





**A****B**



**SUPPLEMENTAL FIGURE 1. (a)** Semi-preparative HPLC chromatogram of crude [<sup>11</sup>C]BU99008 (radioactivity). Agilent Eclipse SB-Phenyl column (250 x 9.4 mm); 50 % acetonitrile: 50% aqueous ammonium formate (50 mM, pH 9.9); 10 mL·min<sup>-1</sup>. **(b)** Semi-preparative HPLC chromatogram of crude [<sup>11</sup>C]BU99008 (UV, 300 nm).

**A**




**B**



**C****D**

E



**SUPPLEMENTAL FIGURE 2.** **(a)** Analytical HPLC chromatograms of purified [ $^{11}\text{C}$ ]BU99008. Agilent Eclipse SB Phenyl column (150 x 4.6 mm); 50% acetonitrile : 50% ammonium formate (50 mM; pH 9.9); 1.5 mL.min $^{-1}$ . **(b)** Analytical HPLC trace of purified [ $^{11}\text{C}$ ]BU99008 (top: Radioactivity, bottom: UV). Agilent Eclipse XDB-C18 column (150 x 4.6 mm); 32% acetonitrile : 68% ammonium formate (50 mM; pH 9); 1.5 mL.min $^{-1}$ . N.B. radioactivity peak appears as multiplet due to saturation of the radioactivity detector. Single peak observed for subsequent coinjection with unlabelled sample of BU99008 (below). **(c)** Analytical HPLC trace of purified [ $^{11}\text{C}$ ]BU99008, coinjected with unlabelled sample of BU99008. Agilent Eclipse XDB-C18 column (150 x 4.6 mm); 32% acetonitrile : 68% ammonium formate (50 mM; pH 9); 1.5 mL.min $^{-1}$ . **(d)** Analytical HPLC trace of purified [ $^{11}\text{C}$ ]BU99008. Agilent Eclipse XDB-C18 column (150 x 4.6 mm); 32% acetonitrile : 68% ammonium formate (50 mM; pH 9); 1.5 mL.min $^{-1}$ . **(e)** Analytical HPLC trace of purified [ $^{11}\text{C}$ ]BU99008, coinjected with unlabelled sample of BU99008. Agilent Eclipse XDB-C18 column (150 x 4.6 mm); 32% acetonitrile : 68% ammonium formate (50 mM; pH 9); 1.5 mL.min $^{-1}$ .

**SUPPLEMENTAL TABLE 1.** Comparative distribution of radioligand binding in selected ROIs in porcine and rat brain

|                               | [ <sup>11</sup> C]BU99008<br>mL/cm <sup>-3</sup> | [ <sup>3</sup> H]2-BFI (1)<br>fmol/mg<br>tissue | [ <sup>3</sup> H]idazoxan<br>(1) fmol/mg<br>tissue |
|-------------------------------|--|---|--|
| <b>Cerebellum</b>             | 26.6   | 6.8   | 7.1  |
| <b>Frontal cortex (whole)</b> | 29.3   | 6.8   | 8.5  |
| <b>Hippocampus</b>            | 36.2   | 9.7   | 11.5   |
| <b>Striatum</b>               | 43.6   | 11.0  | 14.2   |
| <b>Thalamus/Hypothalamus</b>  | 49.7   | 25.2  | 33.7   |

**SUPPLEMENTAL TABLE 2.** Correlation analysis statistics

|  | [ <sup>3</sup> H]2-BFI(28) | [ <sup>3</sup> H]idazoxan<br>(28) |
|--|----------------------------|-----------------------------------|
| <b>Number of XY Pairs</b>                    | 5                          | 5                                 |
| <b>Pearson r</b>                             | <b>0.8688</b>              | <b>0.8804</b>                     |
| <b>P value (one-tailed)</b>                  | <b>0.0279</b>              | <b>0.0244</b>                     |
| <b>P value summary</b>                       | *                          | *                                 |
| <b>Correlation significant? (alpha=0.05)</b> | <b>Yes</b>                 | <b>Yes</b>                        |
| <b>R square</b>                              | <b>0.7548</b>              | <b>0.7751</b>                     |

## **References**

1. Lione LA, Nutt DJ, Hudson AL. Characterization and localization of [<sup>3</sup>H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I<sub>2</sub> receptors. *Eur J Pharmacol.* 1998;353:123-135.